Type 1 diabetes: role of intestinal microbiome in humans and mice

被引:73
作者
Boerner, Brian P. [2 ]
Sarvetnick, Nora E. [1 ,3 ]
机构
[1] Univ Nebraska Med Ctr, Dept Surg, Omaha, NE 68198 USA
[2] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE 68198 USA
[3] Univ Nebraska Med Ctr, Nebraska Regenerat Med Project, Omaha, NE 68198 USA
来源
YEAR IN DIABETES AND OBESITY | 2011年 / 1243卷
关键词
type; 1; diabetes; intestine; microbiome; gliadin; REGULATORY T-CELLS; GENOME-WIDE ASSOCIATION; GERM-FREE MICE; SEGMENTED FILAMENTOUS BACTERIA; PANCREATIC LYMPH-NODES; GUT MICROBIOTA; CELIAC-DISEASE; DENDRITIC CELLS; ESCHERICHIA-COLI; EPITHELIAL-CELLS;
D O I
10.1111/j.1749-6632.2011.06340.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 1 diabetes is a disease involving autoimmune destruction of pancreatic beta cells in genetically predisposed individuals. Identifying factors that trigger initiation and progression of autoimmunity may provide opportunities for directed prophylactic and therapeutic measures to prevent and/or treat type 1 diabetes. The human intestinal microbiome is a complex, symbiotic ecological community that influences human health and development, including the development and maintenance of the human immune system. The role of the intestinal microbiome in autoimmunity has garnered significant attention, and evidence suggests a particular role for intestinal microbiome alterations in autoimmune disease development, including type 1 diabetes. This review will examine the role of the intestinal microbiome in the development and function of the immune system and how this relates to the development of autoimmunity. Data from animal and human studies linking alterations in the intestinal microbiome and intestinal integrity with type 1 diabetes will be closely examined. Finally, we will examine the interactions between the intestinal microbiome and dietary exposures and how these interactions may further influence autoimmunity and type 1 diabetes development.
引用
收藏
页码:103 / 118
页数:16
相关论文
共 134 条
[91]   Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota [J].
Round, June L. ;
Mazmanian, Sarkis K. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (27) :12204-12209
[92]  
Sai P, 1996, DIABETES METAB, V22, P341
[93]   Influence of mode of delivery on gut microbiota composition in seven year old children [J].
Salminen, S ;
Gibson, GR ;
McCartney, AL ;
Isolauri, E .
GUT, 2004, 53 (09) :1388-1389
[94]   Risk Conferred by HLA-DR and DQ for Type 1 Diabetes in 0-35-Year Age Group in Sweden [J].
Sanjeevi, Carani B. ;
Sedimbi, Saikiran K. ;
Landin-Olsson, Mona ;
Kockum, Ingrid ;
Lernmark, Ake .
Immunology of Diabetes V: From Bench to Bedside, 2008, 1150 :106-111
[95]   Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives [J].
Sapone, A ;
de Magistris, L ;
Pietzak, M ;
Clemente, MG ;
Tripathi, A ;
Cucca, F ;
Lampis, R ;
Kryszak, D ;
Cartenì, M ;
Generoso, M ;
Iafusco, D ;
Prisco, F ;
Laghi, F ;
Riegler, G ;
Carratu, R ;
Counts, D ;
Fasano, A .
DIABETES, 2006, 55 (05) :1443-1449
[96]   TREATMENT WITH STREPTOCOCCAL PREPARATION (OK-432) SUPPRESSES ANTI-ISLET AUTOIMMUNITY AND PREVENTS DIABETES IN BB RATS [J].
SATOH, J ;
SHINTANI, S ;
OYA, K ;
TANAKA, SI ;
NOBUNAGA, T ;
TOYOTA, T ;
GOTO, Y .
DIABETES, 1988, 37 (09) :1188-1194
[97]   Delayed exposure to wheat and barley proteins reduces diabetes incidence in non-obese diabetic mice [J].
Schmid, S ;
Koczwara, K ;
Schwinghammer, S ;
Lampasona, V ;
Ziegler, AG ;
Bonifacio, E .
CLINICAL IMMUNOLOGY, 2004, 111 (01) :108-118
[98]   Potential mechanisms by which certain foods promote or inhibit the development of spontaneous diabetes in BB rats - Dose, timing, early effect on islet area, and switch in infiltrate from Th1 to Th2 cells [J].
Scott, FW ;
Cloutier, HE ;
Kleemann, R ;
WoerzPagenstert, U ;
Rowsell, P ;
Modler, HW ;
Kolb, H .
DIABETES, 1997, 46 (04) :589-598
[99]   Ultrastructural mucosal alterations and increased intestinal permeability in non-celiac, type I diabetic patients [J].
Secondulfo, M ;
Iafusco, D ;
Carratù, R ;
deMagistris, L ;
Sapone, A ;
Generoso, M ;
Mezzogiorno, A ;
Sasso, FC ;
Cartenì, M ;
De Rosa, R ;
Prisco, F ;
Esposito, V .
DIGESTIVE AND LIVER DISEASE, 2004, 36 (01) :35-45
[100]  
Serreze DV, 1998, J IMMUNOL, V161, P3912